Establishment and molecular profiling of a novel human pancreatic cancer panel for 5-FU

Cancer Science

Volumn 99, Issue 9, 2008, Pages 1859-1864

  Yanagihara, Kazuyoshi ^a   Takigahira, Misato ^a   Tanaka, Hiromi ^a   Arao, Tokuzo ^b   Aoyagi, Yasuyuki ^c,d   Oda, Tatsuya ^c,d   Ochiai, Atsushi ^c   Nishio, Kazuto ^b  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; K RAS PROTEIN; MESSENGER RNA; PROTEIN P16; PROTEIN P53; SMAD4 PROTEIN; TUMOR MARKER;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CARCINOGENICITY; CELL LINE SUI65; CELL LINE SUI66; CELL LINE SUI67; CELL LINE SUI68; CELL LINE SUI69; CELL LINE SUI70; CELL LINE SUI71; CELL LINE SUI72; CELL LINE SUI73; CELL LINE SUI74; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; ONCOGENE K RAS; PANCREAS CANCER; PRIORITY JOURNAL;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; PANCREATIC NEOPLASMS;

EID: 50149099367     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00896.x     Document Type: Article

References (38)

1. Tsukuma H, Ajiki W, Ioka A, Oshima A. Survival of cancer patients diagnosed between 1993 and 1996: A collaborative study of population-based cancer registries in Japan. Jpn J Clin Oncol 2006; 36: 602-7. Epub 2006 Jul 26.
2. Okusaka T, Matsumura Y, Aoki K. New approaches for pancreatic cancer in Japan. Cancer Chemother Pharmacol 2004; 54: S78-82.
3. Ikeda M, Okada S, Ueno H et al. A phase II study of sequential methotrexate and 5-fluorouracil in metastatic pancreatic cancer. Hepatogastroenterology 2000; 47: 862-5.
4. Ueno H, Okada S, Okusaka T, Ikeda M, Kuriyama H. Phase II study of uracil-tegafur in patients with metastatic pancreatic cancer. Oncology 2002; 62: 223-7.
5. Okada S. Non surgical treatments of pancreatic cancer. Int J Clin Oncol 1999; 4: 257-66.
6. Bhattacharyya M, Lemoine NR. Gene therapy developments for pancreatic cancer. Best Pract Res Clin Gastroenterol 2006; 20: 285-98.
7. Lohr JM. Medical treatment of pancreatic cancer. Expert Rev Anticancer Ther 2007; 7: 533-44.
8. Kato M, Shimada Y, Tanaka H et al. Characterization of six cell lines established from human pancreatic adenocarcinomas. Cancer 1999; 85: 832-40.
9. Ku JL, Yoon KA, Kim WH et al. Establishment and characterization of four human pancreatic carcinoma cell lines. Genetic alterations in the TGFBR2 gene but not in the MADH4 gene. Cell Tissue Res 2002; 308: 205-14. Epub 2002 Apr 11.
10. Kawano K, Iwamura T, Yamanari H, Seo Y, Suganuma T, Chijiiwa K. Establishment and characterization of a novel human pancreatic cancer cell line (SUIT-4) metastasizing to lymph nodes and lungs in nude mice. Oncology 2004; 66: 458-67.
11. Starr AN, Vexler A, Marmor S et al. Establishment and characterization of a pancreatic carcinoma cell line derived from malignant pleural effusion. Oncology 2005; 69: 239-45. Epub 2005 Sept 2.
12. Sato N, Mizumoto K, Beppu K et al. Establishment of a new human pancreatic cancer cell line, NOR-P1, with high angiogenic activity and metastatic potential. Cancer Lett 2000; 155: 153-61.
13. Mohammad RM, Li Y, Mohamed AN et al. Clonal preservation of human pancreatic cell line derived from primary pancreatic adenocarcinoma. Pancreas 1999; 19: 353-61.
14. Kimura Y, Kobari M, Yusa T et al. Establishment of an experimental liver metastasis model by intraportal injection of a newly derived human pancreatic cancer cell line (KLM-1). Int J Pancreatol 1996; 20: 43-50.
15. Ulrich AB, Schmied BM, Standop J, Schneider MB, Pour PM. Pancreatic cell lines: A review. Pancreas 2002; 24: 111-20.
16. Iwamura T, Hollingsworth MA. Pancreatic tumors. In: Master JRW, Palsson B, eds. Human Cell Culture. Great Britain: Kluwer Academic Publishers, 1999; 107-22.
17. Yanagihara K, Tanaka H, Takigahira M et al. Establishment of two cell lines from human gastric scirrhous carcinoma that possess the potential to metastasize spontaneously in nude mice. Cancer Sci 2004; 95: 575-82.
18. Yanagihara K, Takigahira M, Tanaka H et al. Development and biological analysis of peritoneal metastasis mouse models for human scirrhous stomach cancer. Cancer Sci 2005; 96: 323-32.
19. Sun C, Yamato T, Furukawa T, Ohnishi Y, Kijima H, Horii A. Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines. Oncol Rep 2001; 8: 89-92.
20. Yanagihara K, Seyama T, Tsumuraya M, Kamada N, Yokoro K. Establishment and characterization of human signet ring cell gastric carcinoma cell lines with amplification of the c-myc oncogene. Cancer Res 1991; 51: 381-6.
21. Arao T, Yanagihara K, Takigahira M et al. ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model. Int J Cancer 2006; 118: 483-9.
22. Rozenblum E, Schutte M, Goggins M et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997; 57: 1731-4.
23. Loukopoulos P, Kanetaka K, Takamura M, Shibata T, Sakamoto M, Hirohashi S. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas 2004; 29: 193-203.
24. Yatsuoka T, Sunamura M, Furukawa T et al. Association of poor prognosis with loss of 12q, 17p, and 18q, and concordant loss of 6q/17p and 12q/ 18q in human pancreatic ductal adenocarcinoma. Am J Gastroenterol 2000; 95: 2080-5.
25. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M, Danesi R. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther 2006; 5: 1387-95.
26. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53: 549-54.
27. Hruban RH, van Mansfeld AD, Offerhaus GJ et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993; 143: 545-54.
28. Redston MS, Caldas C, Seymour AB et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994; 54: 3025-33.
29. Hahn SA, Schutte M, Hoque AT et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350-3.
30. Wilentz RE, Su GH, Dai JL et al. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: A new marker of DPC4 inactivation. Am J Pathol 2000; 156: 37-43.
31. Caldas C, Hahn SA, da Costa LT et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994; 8: 27-32.
32. Hochster HS, Haller DG, de Gramont A et al. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer 2006; 107: 676-85.
33. Kaneko T, Goto S, Kato A et al. Efficacy of immuno-cell therapy in patients with advanced pancreatic cancer. Anticancer Res 2005; 25: 3709-14.
34. Zhu AX, Clark JW, Ryan DP et al. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. Cancer Chemother Pharmacol 2007; 59: 285-93. Epub 2006 Jun 20.
35. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1.M tegafur-0.4.M gimestat-1.M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998; 34: 1715-20.
36. Rothenberg ML, Moore MJ, Cripps MC et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996; 7: 347-53.
37. Burris HA, 3rd Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15: 2403-13.
38. Aristu J, Canon R, Pardo F et al. Surgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancer. Am J Clin Oncol 2003; 26: 30-6.